GIST data provide another potential Iclusig indication
BioWorld Insight Editor
Ariad Pharmaceuticals Inc. provided positive clinical data for Iclusig. The drug had a rocky start after receiving a December 2012 approval for use in patients with chronic, accelerated and blast phases of CML and Ph+ ALL whose disease is resistant or intolerant to tyrosine kinase inhibitors.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST